On Monday, Tscan Therapeutics Inc (NASDAQ: TCRX) was -11.82% drop from the session before settling in for the closing price of $1.1. A 52-week range for TCRX has been $1.02 – $4.94.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -14.41%. When this article was written, the company’s average yearly earnings per share was at -5.51%. With a float of $46.42 million, this company’s outstanding shares have now reached $52.47 million.
Tscan Therapeutics Inc (TCRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tscan Therapeutics Inc stocks. The insider ownership of Tscan Therapeutics Inc is 18.20%, while institutional ownership is 58.03%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.29 earnings per share (EPS) during the time that was less than consensus figure (set at -0.28) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.18% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
You can see what Tscan Therapeutics Inc (TCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.12, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.90 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Compared to the last year’s volume of 0.52 million, its volume of 0.99 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 20.70%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 0.61%, which indicates a significant decrease from 0.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1535 in the past 14 days, which was higher than the 0.1390 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8191, while its 200-day Moving Average is $1.7103. Nevertheless, the first resistance level for the watch stands at $1.0733 in the near term. At $1.1766, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2332. If the price goes on to break the first support level at $0.9134, it is likely to go to the next support level at $0.8568. Now, if the price goes above the second support level, the third support stands at $0.7535.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
There are 56,748K outstanding shares of the company, which has a market capitalization of 55.04 million. As of now, sales total 2,820 K while income totals -127,500 K. Its latest quarter income was 3,080 K while its last quarter net income were -36,950 K.
